PDF(Pubmed)
Abstract：
BACKGROUND: Breast cancer, particularly triple-negative breast cancer (TNBC), poses a significant global health burden. Chemotherapy was the mainstay treatment for TNBC patients until immunotherapy was introduced. Studies indicate a noteworthy prevalence (0.2% to 18.6%) of mismatch repair protein (MMRP) deficiency in TNBC, with recent research highlighting the potential of immunotherapy for MMRP-deficient metastatic breast cancer. This study aims to identify MMRP deficiency in TNBC patients using immunohistochemistry.
METHODS: A retrospective cohort study design was used and included TNBC patients treated between 2015 and 2021 at King Hussein Cancer Center. Immunohistochemistry was conducted to assess MMRP expression.
RESULTS: Among 152 patients, 14 (9.2%) exhibited deficient MMR (dMMR). Loss of PMS2 expression was observed in 13 patients, 5 of whom showed loss of MLH1 expression. Loss of MSH6 and MSH2 expression was observed in one patient. The median follow-up duration was 44 (3-102) months. Despite the higher survival rate (80.8%, 5 years) of dMMR patients than of proficient MMR patients (62.3%), overall survival did not significantly differ between the two groups.
CONCLUSIONS: Approximately 9% of TNBC patients exhibit dMMR. dMMR could be used to predict outcomes and identify patients with TNBC who may benefit from immunotherapy.
METHODS: A retrospective cohort study design was used and included TNBC patients treated between 2015 and 2021 at King Hussein Cancer Center. Immunohistochemistry was conducted to assess MMRP expression.
RESULTS: Among 152 patients, 14 (9.2%) exhibited deficient MMR (dMMR). Loss of PMS2 expression was observed in 13 patients, 5 of whom showed loss of MLH1 expression. Loss of MSH6 and MSH2 expression was observed in one patient. The median follow-up duration was 44 (3-102) months. Despite the higher survival rate (80.8%, 5 years) of dMMR patients than of proficient MMR patients (62.3%), overall survival did not significantly differ between the two groups.
CONCLUSIONS: Approximately 9% of TNBC patients exhibit dMMR. dMMR could be used to predict outcomes and identify patients with TNBC who may benefit from immunotherapy.
摘要：
背景：乳腺癌，特别是三阴性乳腺癌（TNBC），造成了巨大的全球卫生负担。在引入免疫治疗之前，化疗是TNBC患者的主要治疗方法。研究表明，在TNBC中，错配修复蛋白（MMRP）缺乏症的患病率（0.2％至18.6％），最近的研究强调了免疫疗法治疗MMRP缺陷型转移性乳腺癌的潜力。本研究旨在使用免疫组织化学方法鉴定TNBC患者中的MMRP缺乏。
方法：采用回顾性队列研究设计，纳入2015年至2021年在侯赛因国王癌症中心接受治疗的TNBC患者。进行免疫组织化学以评估MMRP表达。
结果：在152名患者中，14（9.2％）表现出缺乏MMR（dMMR）。在13例患者中观察到PMS2表达的缺失，其中5例显示MLH1表达丧失。在一名患者中观察到MSH6和MSH2表达的缺失。中位随访时间为44（3-102）个月。尽管存活率较高(80.8%，5年）的DMMR患者比熟练的MMR患者（62.3%），两组的总生存期无显著差异.
结论：大约9%的TNBC患者表现出dMMR。dMMR可用于预测结果和确定可能受益于免疫治疗的TNBC患者。
方法：采用回顾性队列研究设计，纳入2015年至2021年在侯赛因国王癌症中心接受治疗的TNBC患者。进行免疫组织化学以评估MMRP表达。
结果：在152名患者中，14（9.2％）表现出缺乏MMR（dMMR）。在13例患者中观察到PMS2表达的缺失，其中5例显示MLH1表达丧失。在一名患者中观察到MSH6和MSH2表达的缺失。中位随访时间为44（3-102）个月。尽管存活率较高(80.8%，5年）的DMMR患者比熟练的MMR患者（62.3%），两组的总生存期无显著差异.
结论：大约9%的TNBC患者表现出dMMR。dMMR可用于预测结果和确定可能受益于免疫治疗的TNBC患者。
